- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02374294
TCOT Effectiveness in Preventing Wound Infections in Perineal Resections
A Prospective, Randomized, Parallel Study Comparing Transdermal, Continuous Oxygen Therapy (TCOT) to Standard of Care to Assess Postoperative Wound Infection Rate in Perineal Resections
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
EPIFLO is a Small, silent disposable, battery-operated oxygen concentrator capable of delivering 98% to 100% oxygen (balance moisture) for seven days at a rate of ~3.0 ml/hour; and 60" long sterile cannula (tube) that conveys the oxygen concentrator to the area beneath the bandage overlying the wound.
The primary objective of this study is to compare the number of surgical site infections associated with perineal surgery within 30 days between subjects randomized to receive EPIFLO or Standard of Care. Secondary Study objectives include Resource utilization and duration of hospitalization.
Hypothesis 1: The proportion of surgical site infections will be lower for patients treated with Transdermal Continuous Oxygen Therapy (TCOT) Hypothesis 2: In the patients who develop infections, wounds will be smaller and heal more rapidly in those treated with Transdermal Continuous Oxygen Therapy.
Key Safety Assessments Include potential dermatological toxicity changes attributed to EPIFLO as measured by observed and reported discomfort and changes in skin during and after the Treatment Period (It is essential to establish the difference between toxicity from the dressing vs. toxicity arising out of EPIFLO).
This Study will be a randomized controlled trial of 30 patients aged 18-80 years who are scheduled to undergo elective perineal resection surgery at the University of Maryland Medical Center. This study is designed to be a Phase II safety & efficacy study. Patients who met the inclusion/exclusion criteria will be randomized to receive the interventional device with Standard of Care or Standard of Care only (1:1). The patients will be equally divided between the two arms. Sham devices are not involved in this study. Wound infections will be diagnosed by the investigator using Centers for Disease Control and Prevention Criteria. As an additional measure to prevent bias, the pictures of the wounds may be sent to an independent clinical specialist for assessment of infection; this specialist will be blinded to get an objective opinion.
The expected time on study is 1 month ( 27-30 days). This does not include screening period which occurs when the subject consents to be in the study (signs the informed consent) to when they have their surgery (day 1). The screening period can be up to 28 days. While in the study, there are four study visits: Visit 1 day 1 is the day of the surgery, and randomization. The second study visit will be the day of the post surgery discharge (day 3-5). The third study visit will be 14 days following surgery, (day 14) and the Final study visit will be the day of the post surgical follow up visit (day 28). The total treatment period may be 14 or 28 days. After 14-days of treatment, if the wound is completely healed, the treatment phase is complete. If the wound is not completely healed they will receive an additional 14 days of treatment. Either way the patient's healing progress will be followed for a total study duration of 30 days.
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Elective perineal resection,
- Patients having abdominal-perineal resections or perineal resections will be included.
- Patient age: 18-80
Exclusion Criteria:
• expected surgery time of less than one hour,
- fever or existing signs of infection at the time of surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Epiflo
After the surgery, but before the application of dressing to the surgical site the kit containing the investigation device (and four cannula) is opened.
The EPIFLO cannula (sterile package) is opened and applied to the surgical site and sealed with the dressings per protocol.
The EPIFLO device is connected to the cannula after making sure the switch is in the ON position.The EPIFLO device is mounted on the patient's body in a convenient location using the Pouch and Arm band provided.
At Treatment Visit 3 (Postoperative day #14, +/- 1 day) a new device is given and the old one disposed of.
Intermittent dressing changes will take place as needed.
|
EPIFLO: Small, silent disposable, battery-operated oxygen concentrator capable of delivering 98% to 100% oxygen (balance moisture) for seven days at a rate of ~3.0 ml/hour; and 60" long sterile cannula (tube) that conveys the oxygen concentrator to the area beneath the bandage overlying the wound.
|
No Intervention: Standard of Care
After the surgery, but before the application of dressing to the surgical site if upon opening, the kit contains only a weighted block, then, the regular wound dressing protocol, standard of care, will be followed.
Intermittent dressing changes will take place as needed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
number of surgical site infections
Time Frame: 30 days
|
number of surgical site infections associated with perineal surgery within 30 days between subjects randomized to receive EPIFLO or Standard of Care.
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
resource utilization (duration of time in hospital)
Time Frame: 30 days
|
30 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EPF-614
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Complication of Surgical Procedure
-
Hannover Medical SchoolKarolinska Institutet; Helsinki University Central Hospital; University of Leipzig and other collaboratorsRecruitingComplication of Surgical ProcedureGermany
-
Stanford UniversityActive, not recruitingComplication of Surgical ProcedureUnited States
-
Fundació Institut de Recerca de l'Hospital de la...UnknownComplication of Surgical ProcedureSpain
-
Zeyong YangUniversity of PennsylvaniaCompletedComplication of Surgical Procedure
-
Hannover Medical SchoolRecruitingComplication of Surgical ProcedureGermany
-
Hospital General Universitario ElcheDr. Negrin University HospitalCompletedCardiovascular Risk Factors of Medical and Septic Complications After Laparoscopic Bariatric SurgeryComplication of Surgical Procedure
-
Eske Kvanner AasvangCompletedComplication of Surgical Procedure | Respiratory Complication | Complication of Anesthesia | Circulatory; ComplicationsDenmark
-
KU LeuvenCompletedComplication of Surgical Procedure | Operation TimeBelgium
-
University of Rome Tor VergataCompletedComplication of Surgical Procedure | Leak; Blood
-
Richard PeruginiUniversity of Massachusetts, WorcesterRecruitingComplication of Surgical Procedure | Resident PhysiciansUnited States
Clinical Trials on Epiflo
-
Neogenix, LLC dba OgenixUniversity of Maryland, College ParkRecruitingIncision | Revascularization | Surgical Wound Healing | Lower ExtremityUnited States
-
Neogenix, LLC dba OgenixWithdrawnInstrumented Spinal FusionUnited States
-
Neogenix, LLC dba OgenixCompleted
-
Neogenix, LLC dba OgenixWithdrawnAnorectal SurgeriesUnited States